Amycretin: Novo Nordisk's Next-Gen Drug That Could Double Wegovy's Weight Loss

If you thought semaglutide was impressive, wait until you hear about amycretin. Novo Nordisk's next-generation obesity drug combines two powerful biological pathways in a single molecule — and the early data suggests it could eventually deliver weight loss that approaches bariatric surgery territory.

Here's what we know, what we don't, and why this matters even if it's years from your medicine cabinet.

What Is Amycretin (Zenagamtide)?

Amycretin — recently renamed zenagamtide by Novo Nordisk — is a unimolecular dual agonist. That means it's a single molecule designed to activate two different receptor systems simultaneously: GLP-1 receptors and amylin receptors.

You already know about GLP-1. That's the pathway semaglutide (Wegovy, Ozempic) targets to suppress appetite, slow gastric emptying, and improve blood sugar control. Amylin is the second piece of the puzzle. It's a hormone co-secreted with insulin from pancreatic beta cells that promotes satiety through a different brain pathway, slows nutrient absorption, and suppresses glucagon — which helps keep blood sugar stable after meals.

By hitting both pathways at once, zenagamtide creates a more comprehensive appetite and metabolic signal than GLP-1 alone. Novo Nordisk's Chief Scientific Officer Martin Holst Lange has described zenagamtide's profile as potentially “best-in-class.”

The Data So Far: Phase 2 Results

Injectable (Once-Weekly)

In a Phase 1b/2a trial of 125 adults with overweight or obesity, once-weekly subcutaneous zenagamtide produced up to 22% weight loss at 36 weeks. That pace was notable because no weight loss plateau was observed at the end of the treatment period — meaning participants were still losing when the study stopped. Published in The Lancet in June 2025.

For context, Wegovy 2.4mg produces about 15-17% weight loss at 68 weeks. Zenagamtide hit 22% at roughly half the time. If the trajectory holds over a full 68-week trial, researchers speculate it could reach 25-30%.

Oral (Once-Daily)

The oral version showed 13.1% weight loss in just 12 weeks at the highest dose tested. That's more than double the rate semaglutide achieves at the same time point. Novo Nordisk noted at their 2024 Capital Markets Day that oral zenagamtide exceeded oral semaglutide's 6% reduction at 12 weeks by a wide margin.

Diabetes Results (Phase 2, November 2025)

In a 448-patient Phase 2 trial in people with type 2 diabetes, the injectable version delivered up to 14.5% weight loss at 36 weeks, while reducing HbA1c by up to 1.8 percentage points. An impressive 89.1% of patients on the injectable achieved HbA1c below 7%. The oral version produced up to 10.1% weight loss and HbA1c reductions up to 1.5% in the same population.

How Is Zenagamtide Different from CagriSema?

Both are Novo Nordisk drugs. Both target GLP-1 and amylin pathways. But they're architecturally different:

CagriSema is a fixed-dose combination of two separate drugs — semaglutide and cagrilintide — combined in a single weekly injection. Think of it as two medicines in one syringe. The Phase 3 REDEFINE 2 trial produced 22.7% weight loss at 68 weeks, which fell short of the 25% target that analysts expected.

Zenagamtide is a single molecule designed from the ground up to activate both receptor types. This matters for manufacturing (one active ingredient vs. two), formulation (can be made into a pill more easily), and potentially for dosing precision. Novo's CSO has said that if zenagamtide matches CagriSema's efficacy, it would be “a very valuable offering” because of its simpler single-molecule design.

Phase 3: The REDEFINE Program

Novo Nordisk began enrolling the Phase 3 REDEFINE program for zenagamtide in obesity during Q1 2026, with both injectable (once-weekly) and oral (once-daily) formulations advancing simultaneously. Separately, Phase 3 trials in type 2 diabetes are planned for H2 2026.

The primary endpoint for obesity will likely be percentage change in body weight from baseline at 68 weeks — the standard benchmark. Thousands of patients will be enrolled across global trial sites.

When Could Zenagamtide Be Available?

Industry analysts (GlobalData) estimate a potential US approval in Q4 2030, with EU approval following in Q1 2031. That assumes Phase 3 trials start on schedule and produce positive results. It's a long road — but the early data is among the most promising in the entire obesity pipeline.

What This Means for Patients Today

Zenagamtide won't be in your medicine cabinet anytime soon. But its development tells us something important: the science of obesity treatment is accelerating rapidly. The drugs available in 2030 will likely be significantly more effective than what we have today — which itself is already transformative.

If you're considering GLP-1 treatment now, the current options (semaglutide, tirzepatide, and the new Wegovy HD 7.2mg) are already producing life-changing results. Starting treatment today builds the metabolic foundation — and if more effective options become available later, you'll be well-positioned to benefit from them.